Not Yet RecruitingNot Applicable

Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging

China64 participantsStarted 2026-04-15

Plain-language summary

The purpose of this study is to use Claudin 18.2 (CLDN18.2)-targeted positron emission tomography (PET) imaging technology to evaluate its detection efficacy and diagnostic threshold for CLDN18.2-positive pancreatic cancer and gastric/gastroesophageal junction cancer, analyze the quantitative value of PET parameters in CLDN18.2 expression and their correlation with prognosis, and provide a basis for the precise selection of CLDN18.2-targeted therapy.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Participants with histopathologically confirmed pancreatic cancer and gastric/gastroesophageal junction cancer with claudin 18.2 expression of any level, including treatment-naive patients with upfront resectable disease, patients with post-operative recurrent disease who are or become resectable following treatment, and patients rendered resectable after neoadjuvant or conversion therapy.
✓. Signed and dated informed consent form.
✓. Commitment to comply with research procedures and co-operation in the implementation of the full research process.
✓. Male or female participants.
✓. Aged 18-75 years old.
✓. Good general performance status with an expected overall survival of more than 6 months.

Exclusion criteria

✕. Participants with prior Claudin 18.2 targeted therapy.
✕. Participants with concurrent other active malignancies.
✕. Participants with severe medical conditions that render them unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
✕. Pregnant women and women who may be pregnant, women who are breastfeeding.
✕. Participants with poor compliance.

What they're measuring

Standardized uptake value(SUV)

Timeframe: Baseline and preoperative assessment at 3 weeks before surgery

The expression level of Claudin-18.2

Timeframe: Baseline and intraoperative specimen collection, assessment within 3 weeks postoperatively

Trial details

NCT IDNCT07554742

SponsorRuijin Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2029-03-31

Contact for this trial

LI Biao

13661777388 lb10363@rjh.com.cn

View on ClinicalTrials.gov More Pancreatic Cancer trials